Amundi Boosts Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Amundi grew its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 56.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,309 shares of the company’s stock after acquiring an additional 14,115 shares during the quarter. Amundi’s holdings in Omnicell were worth $1,694,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Sumitomo Mitsui Trust Group Inc. increased its position in Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock worth $64,573,000 after purchasing an additional 699,925 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of Omnicell by 32.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock worth $67,951,000 after buying an additional 377,883 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Omnicell by 750.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock worth $12,820,000 after buying an additional 259,463 shares during the period. ArrowMark Colorado Holdings LLC raised its position in shares of Omnicell by 27.1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after buying an additional 243,353 shares during the period. Finally, Pier Capital LLC purchased a new stake in Omnicell during the third quarter valued at about $5,859,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Stock Up 0.7 %

Shares of NASDAQ OMCL opened at $33.22 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.75. The stock’s 50-day simple moving average is $40.48 and its 200-day simple moving average is $43.18. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of 123.04, a PEG ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, March 6th. Wells Fargo & Company reduced their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Benchmark reaffirmed a “buy” rating and set a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. raised their price objective on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $52.33.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.